Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$42.12 USD
-0.17 (-0.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $42.09 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Crinetics Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 4 | 5 | 1 | 0 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 4 | 5 | 1 | 0 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 227 | 173 | 109 | 75 | 55 |
Income After Depreciation & Amortization | -223 | -168 | -108 | -75 | -54 |
Non-Operating Income | 13 | 5 | 0 | 1 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -209 | -163 | -108 | -74 | -50 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | -5 | -1 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -215 | -164 | -108 | -74 | -50 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -215 | -164 | -108 | -74 | -50 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -228 | -167 | -106 | -74 | -54 |
Depreciation & Amortization (Cash Flow) | -5 | 1 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -223 | -168 | -108 | -75 | -54 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 58.07 | 51.98 | 38.44 | 30.45 | 24.18 |
Diluted EPS Before Non-Recurring Items | -3.69 | -3.15 | -2.80 | -2.42 | -2.09 |
Diluted Net EPS (GAAP) | -3.69 | -3.15 | -2.80 | -2.42 | -2.09 |
Fiscal Year end for Crinetics Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.35 | 0.99 | 2.68 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.35 | 0.99 | 2.68 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 62.66 | 59.32 | 53.98 | 50.66 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -62.66 | -58.97 | -52.99 | -47.98 |
Non-Operating Income | NA | 6.76 | 2.52 | 2.02 | 1.98 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -55.90 | -56.46 | -50.98 | -46.00 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | -4.20 | -1.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -60.10 | -57.46 | -50.98 | -46.00 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -60.10 | -57.46 | -50.98 | -46.00 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 67.15 | 56.81 | 54.28 | 53.91 |
Diluted EPS Before Non-Recurring Items | NA | -0.90 | -1.01 | -0.94 | -0.85 |
Diluted Net EPS (GAAP) | NA | -0.89 | -1.01 | -0.94 | -0.85 |